<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705870</url>
  </required_header>
  <id_info>
    <org_study_id>JSY_2020_39</org_study_id>
    <nct_id>NCT04705870</nct_id>
  </id_info>
  <brief_title>Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis</brief_title>
  <acronym>COPEQ-MS</acronym>
  <official_title>Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have agreed to participate in the study will complete the MRI protocol as part&#xD;
      of routine care, to which four additional 20-minute sequences will be added.&#xD;
&#xD;
      MRI of routine care in the context of MS includes at least the following sequences:&#xD;
&#xD;
        -  3D T1 TFE (2 minutes)&#xD;
&#xD;
        -  T2 TSE (2 minutes)&#xD;
&#xD;
        -  3D FLAIR (3 minutes)&#xD;
&#xD;
        -  SWI EPI 0.6 iso (7 minutes)&#xD;
&#xD;
      The sequences added by the search are:&#xD;
&#xD;
        -  SWI non EPI QSM 6 echo (10 minutes)&#xD;
&#xD;
        -  SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)&#xD;
&#xD;
        -  SWI EPI to TR equivalent to SWI non EPI (6 minutes)&#xD;
&#xD;
      These sequences will be acquired before or after the injection of gadolinium (if present in&#xD;
      the examination of routine care). For examinations carried out with injection, the order of&#xD;
      carrying out the 4 post-injection SWI sequences will be random.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of lesions showing the central vein sign with the SWI EPI sequence that also show the central vein sign with the candidate sequence</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of lesions which do not present the sign of the central vein with the SWI EPI sequence but which present it with the candidate sequence</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cerebral MRI</intervention_name>
    <description>MRI of routine care in the context of MS includes at least the following sequences:&#xD;
3D T1 TFE (2 minutes)&#xD;
T2 TSE (2 minutes)&#xD;
3D FLAIR (3 minutes)&#xD;
SWI EPI 0.6 iso (7 minutes)&#xD;
The sequences added by the search are:&#xD;
SWI non EPI QSM 6 echo (10 minutes)&#xD;
SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)&#xD;
SWI EPI to TR equivalent to SWI non EPI (6 minutes)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with MS and who should undergo an MRI examination with or without injections of&#xD;
        contrast agent as part of their care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18&#xD;
&#xD;
          -  With MS defined according to the McDonald's revised clinical or radiological spatial&#xD;
             and temporal dissemination criteria, with onset of symptoms &lt;5 years&#xD;
&#xD;
          -  To benefit as part of care from an MRI with or without injection of gadolinium&#xD;
&#xD;
          -  Express consent to participate in the study&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>am√©lie YAVCHITZ</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>julien savatovsky</last_name>
    <phone>0148036401</phone>
    <email>jsavatovsky@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hhopital fondation adolphe de rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelie ya</last_name>
      <phone>0148036454</phone>
      <email>ayavchitz@for.paris</email>
    </contact>
    <investigator>
      <last_name>julien savatovsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

